Co-development of exosome-based thera-
peutics through research collaboration
& option agreements

Novel therapeutic cargo

• Enzymes, antibodies, transcription
  factors, and signaling proteins loaded
  exosome development by combining
  ILIAS’s platforms.

Tissue & organ targeting

• Tissue targeting exosome development
  by using natural tropism of ILIAS’s
  exosome Improving BBB penetration ability
  by applying active targeting moiety
  on the exosome surface Co-development
  of novel targeted therapy by combining
  ILIAS’ platforms and partner’s expertise

Co-develop or outlicense internal pipeline
programs

ILB-202

• Entered phase 1 clinical trial of
  ILB-202 for acute kidney injury (AKI)
• Late-stage clinical trial development
  and commercialization of ILB-202
  through partnering
• Extend development to several chronic
  inflammatory conditions through partnering